Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04184882

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD) Clinical Trial

Official title:
A Randomized, Double Blind, Placebo-Controlled Phase 1b Study With Open-Label Extension to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Patients With Duchenne Muscular Dystrophy (DMD)

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety and tolerability of ASP0367. This study will also evaluate the pharmacokinetics, pharmacodynamics and efficacy on muscle function of ASP0367.

Clinical Trial Description

This study is comprised of a 4-week pre-treatment screening period, 24-week treatment period and 4-week post-treatment follow-up period. The 24-week treatment period consists of a 12-week double-blind (DB) part and 12-week open-label extension (OLE) part and each part includes a 2 week Low dose Period and a 10-week High-dose Period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04184882
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Terminated
Phase Phase 1
Start date February 24, 2021
Completion date September 4, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02814019 - A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids Phase 3
Completed NCT01478022 - To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 Phase 1
Completed NCT00654784 - Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy Phase 2
Recruiting NCT02614820 - The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD N/A
Withdrawn NCT02036463 - A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy Phase 2
Completed NCT02255552 - Study of Eteplirsen in DMD Patients Phase 3
Not yet recruiting NCT06392724 - A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy. Early Phase 1
Completed NCT01982695 - Cardiomyopathy in DMD: Lisinopril vs. Losartan N/A
Recruiting NCT05516745 - E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home" N/A
Completed NCT02420379 - Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Phase 2
Active, not recruiting NCT05135663 - Extension Study of NS-089/NCNP-02 in DMD Phase 2
Completed NCT01380964 - Research of Biomarkers in Duchenne Muscular Dystrophy Patients N/A
Completed NCT05990608 - Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
Recruiting NCT04322357 - Twice Weekly Steroids and Exercise as Therapy for DMD Phase 2
Completed NCT01540409 - Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Phase 2
Terminated NCT04254172 - A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
Recruiting NCT05524883 - Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Phase 1/Phase 2
Completed NCT01761292 - A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD Phase 1/Phase 2